CARLSBAD, Calif. –(BUSINESS WIRE)–Sep. 4, 2026– Ionis Pharmaceuticals, Inc.
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
calendar_today
September 4, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals